(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Autodesk Beats Estimates; Weibo Posts Mixed Results

August 24th, 2023

Autodesk, Inc. (Nasdaq: ADSK), a leading software solutions provider for the design and engineering industries, reported second-quarter fiscal 2024 earnings of $1.91 per share, exceeding the consensus EPS estimate of $1.72. The company's quarterly sa. Read more

Guess? and Splunk Post Better-Than-Expected Earnings, Guide Above-Consensus

August 24th, 2023

Guess?, Inc. (NYSE: GES), a renowned fashion brand known for its clothing and accessories, reported second-quarter fiscal 2024 earnings of $0.72 per share, surpassing the consensus EPS estimate of $0.40. The company's quarterly sales reached $664.51 . Read more

SEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider Trading

August 23rd, 2023

Visiting attorney at the Washington, D.C. office of law firm used access to confidential client info to make illegal profits FOR IMMEDIATE RELEASE 2023-158 Washington D.C. / CRWE PRESS RELEASE / Aug. 23, 2023 -  The Securities and Ex. Read more

NVIDIA Demolishes Wall Street's Q2 Expectations

August 23rd, 2023

NVIDIA Corporation (Nasdaq: NVDA), a leading technology company specializing in graphics processing units and artificial intelligence solutions, reported second-quarter fiscal 2024 earnings of $2.70 per share, surpassing the consensus EPS estimate of. Read more

Mallinckrodt Eyes Chapter 11; Peloton Posts Q4 Loss, Reveals Downbeat Forecast

August 23rd, 2023

Mallinckrodt plc (NYSE American: MNK) said that it has entered into a Restructuring Support Agreement (RSA) with a significant majority of its debtholders and the Opioid Master Disbursement Trust II. The plan aims to reduce the company's debt by arou. Read more

Abercrombie & Fitch Beats Expectations; Foot Locker Posts Mixed Results, Outlook Falls Short

August 23rd, 2023

Abercrombie & Fitch Co. (NYSE: ANF), a well-known apparel retailer, reported second-quarter fiscal 2023 adjusted earnings of $1.10 per share, surpassing the consensus EPS estimate of $0.17. The company's quarterly sales reached $935.30 million, excee. Read more

Market Buzz: Dycom Beats Q2 Estimates; Bullish Stance on Safehold

August 23rd, 2023

Dycom Industries, Inc. (NYSE: DY), a significant player in the infrastructure and specialty contracting sector, reported second-quarter fiscal 2024 earnings of $2.03 per share, surpassing the consensus EPS estimate of $1.66. The company's quarterly s. Read more

Grab Holdings, Bath & Body Works, and Abercrombie & Fitch's Earnings Preview

August 22nd, 2023

Several companies are gearing up to unveil their financial results on Wednesday, August 23, including: Grab Holdings Limited (Nasdaq: GRAB), a significant player in the technology and ride-hailing industry, is set to release its unaudited second q. Read more

Earnings Reactions: Toll Brothers and Urban Outfitters Beat Estimates

August 22nd, 2023

Toll Brothers, Inc. (NYSE: TOL), a prominent luxury homebuilder, reported third-quarter fiscal 2023 earnings of $3.73 per share, surpassing the consensus EPS estimate of $2.81. The company's quarterly sales reached $2.69 billion, exceeding analysts' . Read more

FDA’s Decision Boosts Fulcrum Therapeutics; Macy’s Beats Q2 Estimates

August 22nd, 2023

Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for F. Read more